SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · California · House · Senate · $260,000.00 expenses · posted Jul 16, 2025

Lobbying activity 3

Health Issues

Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to patient access to treatments Issues related to newborn screening for rare diseases

Science/Technology

Issues related to scientiﬁc innovation in healthcare such as gene therapies Issues related to artiﬁcial intelligence and data governance

Taxation/Internal Revenue Code

Tax issues related to research and development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.